Navigation Links
Sinovac Announces Management Changes
Date:8/5/2011

BEIJING, Aug. 5, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for a new Chief Financial Officer to replace Mr. Ho, who has agreed to remain with the Company until August 16, 2011.  Ms. Nan Wang, Vice President of Sinovac, has been appointed as the Interim Chief Financial Officer.

Ms. Wang has served as the Vice General Manager of Sinovac Beijing, the Company's primary operating subsidiary, since 2001, and in other senior management roles. She oversees Sinovac's business development, strategic management and investment. She was instrumental in leading Sinovac's successful public offering in early 2010. Ms. Wang received her Bachelor of Science degree in Biology from Peking University and her Master of Business Administration's degree from the University of International Business and Economics, Beijing PRC. She also holds a Diploma in Financial Management, jointly issued by The Association of Chartered Certified Accountants (ACCA) and Beijing College for Entrepreneurs.

Sinovac's external auditor continues to be Ernst & Young LLP., which has audited the Company since 2005.

Mr. Weidong Yin, Chairman, President and CEO, stated, "We appreciate Jacob's contributions to the Company and wish Jacob the best in his future endeavors. Nan continues to be a valuable member of the Company's senior management team and has been instrumental in implementing our corporate strategy over the past decade. As the Interim Chief Financial Officer, she will provide for a smooth transition as the Company searches for a new Chief Financial Officer."

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuant to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Contacts:Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: scarrington@theruthgroup.comMedia:Victoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: vaguiar@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Holds 2011 Annual Shareholders Meeting
2. Sinovac Appoints Kenneth Lee to Board of Directors
3. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
4. Sinovac Reports Unaudited First Quarter 2011 Financial Results
5. Sinovac Presents at Two Investor Conferences in May 2011
6. Sinovac Files Annual Report on Form 20-F
7. Sinovac Participates in UBS Greater China Healthcare Corporate Day
8. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
9. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
10. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
11. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... , Jan. 12, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... from February 10, 2014 through November 9, 2016, inclusive ... for Alexion investors under the federal securities laws. ... http://rosenlegal.com/cases-991.html or call Phillip Kim, Esq. ...
(Date:1/12/2017)... 12, 2017 The global peripheral intravenous ... reaching beyond US$ 3.8 Bn by 2016 end. Wide adoption of ... fuel the demand for PIVC. Rising disease prevalence will play a ... is likely to remain the largest market; ... rate. ...
(Date:1/12/2017)... , Jan. 12, 2017 This ... global magnetic resonance imaging (MRI) systems market by ... region. Forecasts included from 2016 through 2021. ... market for medical magnetic resonance imaging (MRI) systems ... field strength and region. - Gain insight into ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in Lung Cancer ... 2017. This Congress is expertly designed to meet the educational needs of European ... cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at the University ...
(Date:1/13/2017)... ... January 13, 2017 , ... KOAMTAC ®, Inc., a leading ... the next generation companion scanner and data collector at the National Retail Federation’s Big ... created as an answer to the market’s need for more compact and rugged devices ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... ... ... People who have sensitive teeth are about as common as those who do ... dental hygiene products in the market contain chemical ingredients that only aggravate the condition ... oral care routine to keep their teeth white and healthy is a struggle with ...
(Date:1/13/2017)... Okla. (PRWEB) , ... January 13, 2017 , ... Friday, ... the area of the game room, increasing the size of the location to 90,000 ... Course, an 8-hole mini golf course that takes customers on an educational tour of ...
Breaking Medicine News(10 mins):